Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
+ Filter
Loading...
Custom Services order now ship next day

Anti-CD137 Recombinant Antibody Products

Engineered Antibody Products Antibody-like Scaffold Protein Products Glyco-Engineering Antibody Products AbPlus Recombinant Antibody Products Functional Antibody Products Formats

Creative Biolabs provides a comprehensive range of CD137-targeted recombinant antibodies to customers worldwide, leveraging our cutting-edge technologies. Our industry-leading resources and team provide exceptional value in moving research forward and assisting global customers in meeting their research objectives.

CD137: A Promising Target in Cancer Immunotherapy

Activation of CD137 (4-1BB /CD137/ILA), a receptor found on activated T cells and numerous other immune cells, triggers signaling pathways crucial for a strong cellular immune response. Due to its capability to regulate various immune cells and its significant role in promoting T cell survival, proliferation, and effector functions, 4-1BB has emerged as a promising target in the advancement of cancer immunotherapy.

Anti-CD137 Recombinant Antibody Products

Our goal is to drive research and innovation forward by providing high-quality anti-CD137 recombinant antibodies at an outstanding value, along with exceptional technical support. Below we offer a selection of premium anti-CD137 recombinant antibodies to choose from for your meaningful needs.

Cat. No. Product Name Target Species Host Species Applications
TAB-179 Anti-Human 4-1BB Recombinant Antibody (Urelumab) Human Human IgG4-kappa ELISA, FC, IP, FuncS, IF, Neut, ICC
TAB-457CQ Anti-Human CD137 Recombinant Antibody Human Human IgG2, λ ELISA, IHC, FC, IP, IF, FuncS
FN-078CQ Rat Anti-CD137 Recombinant Antibody (clone 3H3) Mouse Rat IgG2a, κ FuncS
HPAB-0257-CN Human Anti-CD137 Recombinant Antibody Human Human IgG FC
HPAB-0814LY Human Anti-CD137 Recombinant Antibody Human Human IgG1 FC, FuncS

Creative Quality Control

We are dedicated to supporting the biopharmaceutical sector by pushing the boundaries of research and development with our superior product quality and outstanding customer support. By harnessing a robust quality management system, we are committed to enhancing the drug development journey but also delivering exceptional value to our customers, ensuring their research needs are consistently met with excellence.

Fig.1 WB analysis of anti-4-1BB therapeutic antibody (TAB-179). (Creative Biolabs Original)Fig.1 Anti-Human 4-1BB Therapeutic Antibody (Urelumab) in WB.
(Cat# TAB-179, Creative Biolabs).

Fig.2 ELISA analysis of anti-4-1BB therapeutic antibody (TAB-179). (Creative Biolabs Original)Fig.2 Anti-Human 4-1BB Therapeutic Antibody (Urelumab) in ELISA.
(Cat# TAB-179, Creative Biolabs).

Fig.3 Dot plot analysis of anti-4-1BB therapeutic antibody (TAB-179). (Creative Biolabs Original)Fig.3 Anti-Human 4-1BB Therapeutic Antibody (Urelumab) in Dot Blot.
(Cat# TAB-179, Creative Biolabs).

Fig.4 SDS-PAGE analysis of anti-CD137 recombinant antibody (TAB-457CQ). (Creative Biolabs Original)Fig.4 Anti-Human CD137 Recombinant Antibody-Low endotoxin in SDS-PAGE.
(Cat# TAB-457CQ, Creative Biolabs).

Fig.5 WB analysis of anti-CD137 recombinant antibody (TAB-457CQ). (Creative Biolabs Original)Fig.5 Anti-Human CD137 Recombinant Antibody-Low endotoxin in WB.
(Cat# TAB-457CQ, Creative Biolabs).

Fig.6 ELISA analysis of anti-CD137 recombinant antibody (TAB-457CQ). (Creative Biolabs Original)Fig.6 Anti-Human CD137 Recombinant Antibody in ELISA.
(Cat# TAB-457CQ, Creative Biolabs).

Customer Reviews

Excellent
User 17*****3
Anti-Human 4-1BB Recombinant Antibody (Urelumab) (CAT#: TAB-179)
I acquired this product specifically for IP assays and was pleasantly surprised by its outstanding specificity and bioactivity, making it perfect for my needs. Additionally, the positive rate exceeded my expectations. The cost is also very affordable, and the customer support is outstanding. Overall, I am highly pleased with this purchase.
27/Jan/2024 3 Likes
Excellent
Cu***n
Afuco™ Anti-CD137 ADCC Recombinant Antibody (Urelumab), ADCC Enhanced (CAT#: AFC-TAB-179)
I recently acquired an ADCC-enhanced anti-CD137 antibody from Creative Biolabs, and the results have been remarkable. This antibody effectively induced a significantly higher ADCC effect in mice compared to standard antibodies. Additionally, it achieved a pronounced ADCC response with only minimal quantities of the antibody, demonstrating its potency and efficiency.
17/Jun/2024 1 Likes
Excellent
Am***r
Human Anti-CD137 Recombinant Antibody (HPAB-M0333-YC)
I employed this antibody as an agonist to confirm the effectiveness of my CD137 pathway silencing, and the outcomes aligned perfectly with my expectations. During my purchase, the customer service team not only suggested the optimal concentration but also provided insights into potential scenarios. Excellent experience!
25/Oct/2023 3 Likes

Anti-CD137 Recombinant Antibody Production

Leveraging our state-of-the-art technology and extensive expertise, we provide end-to-end solutions for producing high-quality anti-CD137 recombinant antibodies. From gene synthesis to large-scale manufacturing, our optimized processes ensure swift, reliable, and cost-effective antibody production tailored to your needs, all backed by over 5 years of industry experience.

Featured Anti-CD137 Recombinant Antibody Production Platforms

Fig.7 Anti-CD137 recombinant antibody production: Milligram-scale. (Creative Biolabs Original)Fig.7 Milligram-scale anti-CD137 recombinant antibody production.

Fig.8 Anti-CD137 recombinant antibody production: Gram-scale. (Creative Biolabs Original)Fig.8 Gram-scale anti-CD137 recombinant antibody production.

Anti-CD137 Recombinant Antibody Modalities

Creative Biolabs specializes in providing groundbreaking recombinant antibodies tailored for the research community. Our comprehensive portfolio includes anti-CD137 antibodies in multiple formats, including full-length antibodies, Fab fragments, and single-chain variable fragments (scFv). With our deep expertise and proven proficiency in antibody engineering, we are well-equipped to offer bespoke solutions designed to accommodate your unique research requirements.

Fig.9 The production and modalities of full-length anti-CD137 recombinant antibody. (Creative Biolabs Original)Fig.9 Full-Length Anti-CD137 Recombinant Antibody Production and Modalities.

Alternative Names

TNF Receptor Superfamily Member 9; T-Cell Antigen 4-1BB; 4-1BB; T-cell antigen ILA; Induced By Lymphocyte Activation; ILA; CD137 Antigen; CDw137; CD137; Interleukin-Activated Receptor; Homolog of Mouse Ly63; 4-1BB Ligand Receptor.

Background

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. The expression of this receptor is induced by lymphocyte activation. TRAF adaptor proteins have been shown to bind to this receptor and transduce the signals leading to activation of NF-kappaB.
Protein class

Cancer-related genes, CD markers

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Cell type enhanced (granulocytes, monocytes, T-cells, Langerhans cells, dendritic cells)

Immune cell specificity

Group enriched (T-reg, memory CD8 T-cell, neutrophil, NK-cell)

Cell line specificity

Cell line enriched (HDLM-2)

Interaction

Interacts with TRAF1, TRAF2 and TRAF3. Interacts with LRR-repeat protein 1/LRR-1.

Molecular function

Receptor

More Types Infomation

Drug Information Targeting CD137

Table 1. CD137-targeted drug information.

Company Company Condition Indication
Launched - 2023 Immunoadoptive Cell Therapy Lymphoma, B-cell Treatment of B-cell lymphomas where one or more lines of treatment have failed or have been rendered inadequate or insufficient to render a response
Launched - 2022 Bristol-Myers Squibb Multiple myeloma Treatment of adult patients who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and have experienced disease progression or relapse after the last therapy
Launched - 2021 2seventy bio Multiple myeloma Treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody
Launched - 2022 Bristol-Myers Squibb B-cell leukemia Second-line therapy of recurrent or refractory large B-cell lymphoma
Launched - 2024 Bristol-Myers Squibb Chronic lymphocytic leukemia Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor
Launched - 2021 Bristol-Myers Squibb Lymphoma, B-cell Treatment of adult patients with relapsed or refractory high-grade B-cell lymphoma after two or more lines of systemic therapy; Treatment of adult patients with relapsed or refractory high-grade B-cell lymphoma who have refractory disease to first-line chemoimmunotherapy, relapse within 12 months of first-line chemoimmunotherapy including who are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age
Launched - 2024 Bristol-Myers Squibb Lymphoma, small lymphocytic Treatment of adult patients with relapsed or refractory small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor
Registered - 2023 Bristol-Myers Squibb Lymphoma, B-cell In adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy
Phase I Seattle Children's Hospital Acute lymphocytic leukemia Treatment of children and young adults (aged 1 to 26) with relapsed CD19+ acute lymphoblastic leukemia, following cyclophosphamide administration
Registered - 2023 Juventas Cell Therapy B-cell acute lymphocytic leukemia For adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

If you require more information about our anti-CD137 recombinant antibodies, please do not hesitate to contact us at your convenience. We are excited to embark on a collaborative journey and support your research endeavors with our specialized products and services.

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

For Research Use Only. Not For Clinical Use.

  • 0
  • 0
Cart
    Inquiry
    Go to compare

    Go to compare